We serve 4-Guanidinobenzoic acid hydrochloride CAS:42823-46-1 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name: 4-Guanidinobenzoic acid hydrochloride
CAS.NO: 42823-46-1
Synonyms:
4-Guanidino-benzoesaeure,Hydrochlorid
N-(carboxypheny)guanidine hydrochoride
4-aminoiminomethylaminobenzoic acid.hydro-chloride
4-carbamimidamidobenzoic acid hydrochloride
4-Guanidinobenzoic a
Molecular Formula: C8H10ClN3O2
Molecular Weight: 215.63700
Physical and Chemical Properties:
Boiling point: 438.4ºC at 760 mmHg
Melting point: 285 ° C (dec.) (Lit.)
Flash point: 218.9ºC
Specification:
Appearance: Off-White Solid
Purity:≥99.0%
Specific rotation:+39.5 to +41.5°
State of solution(transmittance):Clear 98.0% min.
Chloride[cl]:0.020% max.
Ammonium [NH4]:0.02% max.
Sulfate[SO4]:0.020% max
Iron[Fe]:10ppm max.
Heavy metals [Pb]:10ppm max
Arsenic[As2O3]:1ppm max
Other amino acids:Chromatographically not detectable
Loss on drying:0.20% max.
Residue on ignition[sulfated]:0.10% max.
Contact us for information like 4-Guanidinobenzoic acid hydrochloride chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4-Guanidinobenzoic a physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4-aminoiminomethylaminobenzoic acid.hydro-chloride Use and application,N-(carboxypheny)guanidine hydrochoride technical grade,usp/ep/jp grade.
Related News: With the structural upgrade of the pharmaceutical industry in developed countries, the transfer of related industrial chains has taken place globally, and it has also had a profound impact on Chinese pharmaceutical companies. near2-(Trifluoromethoxy)aniline manufacturer This dosage form may also support combination therapy modalities.? To date, over 400 patients have been dosed with the oral formulation of rigosertib in clinical trials.? Combination therapy of oral rigosertib with azacitidine, the standard of care in HR-MDS, has also been studied. Currently, oral rigosertib is being developed as a combination therapy together with azacitidine for patients with higher-risk MDS who require HMA therapy.?Cyclopropanecarbonyl Chloride supplier This dosage form may also support combination therapy modalities.? To date, over 400 patients have been dosed with the oral formulation of rigosertib in clinical trials.? Combination therapy of oral rigosertib with azacitidine, the standard of care in HR-MDS, has also been studied. Currently, oral rigosertib is being developed as a combination therapy together with azacitidine for patients with higher-risk MDS who require HMA therapy.?2,3,4,5-Tetrachloronitrobenzene vendor The risk to the UK population has been raised from very low to low, according to Public Health England, which says the country is “well prepared for new diseases”.Hong Kong confirmed its 14th coronavirus case late Saturday. The patient, an 80-year-old man, had traveled for a few hours to mainland China in early January, and later spent several days on a cruise ship in Japan with more than 3,000 passengers and employees.
